Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)

Next Previous
Search
Trial Profile

Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipatasertib (Primary) ; Pembrolizumab (Primary) ; Pictrelisib (Primary) ; Dactolisib
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Feb 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 27 Nov 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.
    • 27 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top